Citi Begins Hikma Pharmaceuticals Coverage at Buy

08:33 AM EDT, 07/16/2026 (MT Newswires) -- Citi on Thursday started its coverage of British pharmaceutical company Hikma Pharmaceuticals (HIK.L) with a buy rating and a price target of 17 pounds sterling. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)